TAIPEI, Taiwan, July 25th , 2019 -- Senhwa Biosciences, Inc. (TPEx: 6492) announced today that the clinical trial of Silmitasertib (CX-4945) for the treatment of Medulloblastoma (MB) has enrolled its first patient at Cincinnati Children’s Hospital Medical Center, Ohio, USA. The trial will be carried out simultaneously across multiple clinical centers in the United States.
Medulloblastoma (MB) is the most common cancerous brain tumor in children. Treatment for Medulloblastoma usually includes surgery followed by radiation or chemotherapy, or both. Currently there is no targeted drug available for the treatment of MB. Children with MB need to be seen by pediatric specialists with experience treating pediatric brain tumors.
The Pediatric Brain Tumor Consortium (PBTC, www.pbtc.org) will conduct a Phase I/II and Surgical study of Silmitasertib in both children and adults with recurrent SHH (sonic hedgehog) medulloblastoma at its participating member academic medical centers and children’s hospitals across the United States (see Table I for a complete list). This clinical trial is sponsored by the PBTC and funded thorough the Consortium grant awarded by the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI).
SHH is recognized as one of the 4 major sub-groups of medulloblastoma with an estimated 80-100 newly diagnosed cases per year. Objectives of the study include establishing the safety, tolerability, pharmacokinetics and preliminary evidence of activity for Silmitasertib in children and adults with recurrent SHH MB.
In preliminary research conducted by Stanford University School of Medicine using Senhwa’s Silmitasertib, showed the potential to treat MB. Senhwa is looking forward to clinical progress, and is hoping that a medical benefit will be made available in the near future to those who suffer from medulloblastoma